Rafferty Asset Management LLC Boosts Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Rafferty Asset Management LLC grew its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 31.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 513,128 shares of the biotechnology company's stock after purchasing an additional 122,173 shares during the quarter. Rafferty Asset Management LLC owned about 0.22% of ADMA Biologics worth $8,800,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock worth $865,000 after buying an additional 645 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock worth $954,000 after buying an additional 700 shares during the period. Summit Investment Advisors Inc. grew its position in shares of ADMA Biologics by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock worth $404,000 after buying an additional 746 shares during the period. Mutual of America Capital Management LLC grew its position in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after buying an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System grew its position in shares of ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock worth $1,365,000 after buying an additional 897 shares during the period. 75.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. Raymond James raised their price target on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Finally, StockNews.com downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $24.25.

ADMA Biologics Stock Performance

Shares of NASDAQ ADMA traded up $0.25 during trading on Tuesday, reaching $20.44. 2,452,733 shares of the company traded hands, compared to its average volume of 3,706,533. The firm has a 50 day simple moving average of $20.52 and a 200-day simple moving average of $18.88. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $4.88 billion, a PE ratio of 73.00 and a beta of 0.57. ADMA Biologics, Inc. has a 52-week low of $9.31 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. During the same quarter last year, the company earned $0.08 EPS. ADMA Biologics's revenue for the quarter was up 40.2% on a year-over-year basis. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.